A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Lay Description
Category
- Heart, Vascular and Blood
- IRB Number
- 20220477HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Regulatory Point of Contact
Andrea Hansis-diarte
+1 (210) 617-5300
hansisdiarte@uthscsa.edu
Regulatory Point of Contact
Italia Herrera
(210) 567-2687
herrerai1@uthscsa.edu
Regulatory Point of Contact
Johnnie Jones
(210) 450-7277
jonesj21@uthscsa.edu
Regulatory Point of Contact
Lorannys Sanchez Tamarez
(210) 450-8332
sancheztamar@uthscsa.edu
Principal Investigator
Allen Anderson